<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177331</url>
  </required_header>
  <id_info>
    <org_study_id>231.215</org_study_id>
    <nct_id>NCT02177331</nct_id>
  </id_info>
  <brief_title>Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>Lacidipine in Medical Practice: Incidence of Rare Adverse Drug Reactions During Long-term Treatment. 3rd Follow-up Study - Long-term Use in the 4th and 5th Year Treatment Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to&#xD;
      provide long-term data on its impact on liver function, glucose homoeostasis and lipid&#xD;
      metabolism. Additionally, its adverse drug reactions and antihypertensive effects were to be&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1995</start_date>
  <primary_completion_date type="Actual">January 1998</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with rare adverse drug reactions</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in alkaline phosphatase (AP)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum glutamic - pyruvic transaminase (SGPT)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum glutamic - oxaloacetic transaminase (SGOT)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic and diastolic blood pressure</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gamma glutamyl transferase (gamma-GT)</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Lacidipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacidipine</intervention_name>
    <arm_group_label>Lacidipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfillment of entry criteria for the preceding yearly study&#xD;
&#xD;
          -  Male or female patients aged between 20 and 85 years&#xD;
&#xD;
          -  Known history of mild to moderate essential hypertension requiring drug treatment, WHO&#xD;
             grade I to II&#xD;
&#xD;
          -  Controlled blood pressure (RR diastolic â‰¤ 90 mm Hg or 91 - 95 mm Hg and concurrent&#xD;
             reduction in blood pressure of at least 10 mm compared to baseline level) during&#xD;
             treatment with lacidipine at a dose of 2 - 6 mg once a day&#xD;
&#xD;
          -  Final visit of the previous yearly study (Visit 4) completed as scheduled&#xD;
&#xD;
          -  Informed consent to participate in the follow-up study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Violation of entry/exclusion criteria on enrolment in the preceding yearly study&#xD;
&#xD;
          -  Occurrence of the following exclusion criteria in the intervening period:&#xD;
&#xD;
               -  Pregnancy, lactation, possibility of conception without the use of a&#xD;
                  scientifically recognised method of contraception&#xD;
&#xD;
               -  Secondary form of hypertension&#xD;
&#xD;
               -  Consumptive illness&#xD;
&#xD;
               -  Clinically manifest concomitant cardiovascular illness, e.g.: aortic or mitral&#xD;
                  valve stenosis, hypertrophic obstructive cardiomyopathy or any other condition&#xD;
                  hindering left ventricular outflow, aortic isthmus stenosis, severe (NYHA Class&#xD;
                  III or higher) or decompensated heart failure, clinically relevant hypo- or&#xD;
                  hyperkinetic cardiac arrhythmia&#xD;
&#xD;
               -  Myocardial infarction or cerebrovascular accident within the 6 months prior to&#xD;
                  the start of the follow-up study&#xD;
&#xD;
               -  Hypersensitivity to dihydropyridines&#xD;
&#xD;
               -  Concomitant long-term treatment (&gt; 3 weeks) with antihypertensive substances not&#xD;
                  envisaged in the protocol (exception: short-acting nitrates), sedatives,&#xD;
                  tricyclic antidepressants&#xD;
&#xD;
               -  Suspected alcohol, narcotic or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/231/231.215_U99-1368.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

